Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Aniracetam | DMAE (Dimethylaminoethanol) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 750-1500 mg/day divided into 2-3 doses | 150-400 mg/day (as DMAE bitartrate, typically 37% DMAE) |
| Timing | With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat) | Morning. With or without food. |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off | Ongoing; no strict cycling required |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Potent positive allosteric modulator of AMPA receptors with 5-10x the potency of piracetam, slowing both channel closing rate and microscopic desensitization rates. Also modulates metabotropic glutamate receptors (mGluRs), activates nicotinic acetylcholine receptors, and indirectly boosts dopaminergic and serotonergic neurotransmission, conferring anxiolytic properties.
750-1500 mg/day divided into 2-3 doses
With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat)
Cycles of 8-12 weeks on, 4 weeks off
Structural analog of choline that crosses the BBB more readily than choline itself. Paradoxically increases choline availability not by serving as a direct precursor to acetylcholine, but by inhibiting choline metabolism in peripheral tissues, thereby increasing circulating choline available for brain uptake. Also acts as a free radical scavenger and membrane stabilizer. Reduces lipofuscin accumulation in neuronal cells, an age pigment associated with cellular aging.
150-400 mg/day (as DMAE bitartrate, typically 37% DMAE)
Morning. With or without food.
Ongoing; no strict cycling required
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →